BACKGROUND: A recent rise in the incidence of prostate cancer and a more favorable outcome have increased the proportions of other causes of death in affected men. Extending the survival of prostate cancer patients thus requires knowledge of all causes of death. METHODS: Data on the population, cancers, and causes of death were gathered from the nationwide Swedish Family-Cancer Database. A Cox regression model, comparing prostate cancer patients with all other men, was applied. Hazard ratios (HR) were calculated both for the underlying cause and for dying with a specific cause listed among multiple causes of death. FINDINGS: Among 686,500 observed deaths, 62,500 were prostate cancer patients. For underlying causes other than prostate cancer, the highest cause-specific HRs were found for external causes (HR, 1.24; 95% confidence interval [CI], 1.16-1.31), diseases of the pulmonary circulation (HR, 1.22; 95% CI, 1.09-1.37), and heart failure (HR, 1.18; 95% CI, 1.11-1.24). For specific multiple causes, the highest HRs were found for anemia (HR, 2.28; 95% CI, 2.14-2.42), diseases of the pulmonary circulation (HR, 1.61; 95% CI, 1.55-1.68), and urinary system disease (HR, 1.90; 95% CI, 1.84-1.96). INTERPRETATIONS: Prostate cancer patients have a higher risk for dying from various causes other than prostate cancer, including external causes and heart failure. Mechanisms have been proposed linking these elevated risks to both cancer and treatment. More attention should be paid to comorbidities in men with prostate cancer. The present study fulfills a gap in the knowledge of death causes in prostate cancer patients.
BACKGROUND: A recent rise in the incidence of prostate cancer and a more favorable outcome have increased the proportions of other causes of death in affected men. Extending the survival of prostate cancerpatients thus requires knowledge of all causes of death. METHODS: Data on the population, cancers, and causes of death were gathered from the nationwide Swedish Family-Cancer Database. A Cox regression model, comparing prostate cancerpatients with all other men, was applied. Hazard ratios (HR) were calculated both for the underlying cause and for dying with a specific cause listed among multiple causes of death. FINDINGS: Among 686,500 observed deaths, 62,500 were prostate cancerpatients. For underlying causes other than prostate cancer, the highest cause-specific HRs were found for external causes (HR, 1.24; 95% confidence interval [CI], 1.16-1.31), diseases of the pulmonary circulation (HR, 1.22; 95% CI, 1.09-1.37), and heart failure (HR, 1.18; 95% CI, 1.11-1.24). For specific multiple causes, the highest HRs were found for anemia (HR, 2.28; 95% CI, 2.14-2.42), diseases of the pulmonary circulation (HR, 1.61; 95% CI, 1.55-1.68), and urinary system disease (HR, 1.90; 95% CI, 1.84-1.96). INTERPRETATIONS: Prostate cancerpatients have a higher risk for dying from various causes other than prostate cancer, including external causes and heart failure. Mechanisms have been proposed linking these elevated risks to both cancer and treatment. More attention should be paid to comorbidities in men with prostate cancer. The present study fulfills a gap in the knowledge of death causes in prostate cancerpatients.
Authors: L Joseph Melton; Khalid I Alothman; Sundeep Khosla; Sara J Achenbach; Ann L Oberg; Horst Zincke Journal: J Urol Date: 2003-05 Impact factor: 7.450
Authors: P Maisonneuve; L Agodoa; R Gellert; J H Stewart; G Buccianti; A B Lowenfels; R A Wolfe; E Jones; A P Disney; D Briggs; M McCredie; P Boyle Journal: Lancet Date: 1999-07-10 Impact factor: 79.321
Authors: Matthew R Smith; Joel S Finkelstein; Francis J McGovern; Anthony L Zietman; Mary Anne Fallon; David A Schoenfeld; Philip W Kantoff Journal: J Clin Endocrinol Metab Date: 2002-02 Impact factor: 5.958
Authors: Mieke Van Hemelrijck; Jan Adolfsson; Hans Garmo; Anna Bill-Axelson; Ola Bratt; Erik Ingelsson; Mats Lambe; Pär Stattin; Lars Holmberg Journal: Lancet Oncol Date: 2010-04-13 Impact factor: 41.316
Authors: Shehzad Basaria; John Lieb; Alice M Tang; Theodore DeWeese; Michael Carducci; Mario Eisenberger; Adrian S Dobs Journal: Clin Endocrinol (Oxf) Date: 2002-06 Impact factor: 3.478